摘要
食管癌是我国常见的恶性肿瘤之一,死亡率高,预后较差,总5年生存率20%左右[1],70%～80%的患者在就诊时已属晚期,中位生存期为4个月～8个月[2].
出处
《肿瘤预防与治疗》
2010年第2期178-180,171,共4页
Journal of Cancer Control And Treatment
参考文献20
-
1Mariette C,Finzi L,Fabre S,et al.Factors predictive of complete resection of operable esophageal cancer:a prospective study[J].Ann Thorac Surg,2003,75(6):1720-1726.
-
2Muro K,Hamaguchi T,Ohtsu A,et al.A phase Ⅱ study of single agent docetaxel in patients with metastatic esophageal cancer[J].Annals of Oncology,2004,15(6):955-959.
-
3Cho SH,Chung IJ,Song SY,et al.Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer[J].J Korean Med Sci,2005,20(4):618-623.
-
4Zhang X,Shen L,Li Y,et al.A phase Ⅱtrial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus[J].Am J Clin Oncol,2008,31(1):29-33.
-
5Lin CC,Yeh KH,Yang CH,et al.Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma[J].Anticancer Drugs,2007,18(6):703-708.
-
6EI-Rayes BF,Shields A,Zalupski M,et al.Aphase Ⅱ study of carboplatin and paclitaxel in esophageal cancer[J].Ann Oncol,2004,15(6):960-965.
-
7Cao W,Xu C,Lou G,et al.A phase Ⅱ study of paclitsxel and nedaphtin as first-line chemotherapy in patients with advanced esophageal cancer[J].Jpn J Clin Oncol,2009,39(9):582-587.
-
8Gong Y,Ren L,Zhou L,et al.Phase Ⅱ evaluation of nedaplatin and paclitsxel in patients with metastatic esophageal carcinoma[J].Cancer Chemother Pharmacol,2009,64(2):327-333.
-
9Schull B,Komek GV,Schmid K,et al.Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietie growth factor support in patients with advanced gastroesophageal cancer[J].Oncology,2003,65(3):211-217.
-
10Nakajima Y,Suzuki T,Haruki S,et al.A pilot trial of docetaxel and nedaplatinin cisphtin-pretreated relapsed or refractory esophageal squamous cell cancerp[J].Hepatogastroenterolagy,2008,55(86-87):1631-1635.
同被引文献10
-
1伍福胜.顺铂联合氟尿嘧啶治疗恶性腹水的临床观察[J].肿瘤研究与临床,2004,16(4):267-268. 被引量：6
-
2朱正秋,黄广清,赵晶.低剂量氟尿嘧啶持续静脉输注治疗晚期胃癌的临床研究[J].徐州医学院学报,2004,24(5):436-438. 被引量：3
-
3钱勇,张从军,陈振东.食管癌化疗患者生活质量评价133例[J].世界华人消化杂志,2006,14(18):1819-1823. 被引量：8
-
4郭仁宏,张全安,唐桂棣,潘良熹,黄新恩,冯继锋.周剂量紫杉醇联合LFP方案治疗晚期食管癌的临床研究[J].临床肿瘤学杂志,2006,11(11):825-827. 被引量：5
-
5张从军,钱勇,陈振东.化疗在食管癌综合治疗中的研究现状[J].临床肿瘤学杂志,2006,11(11):870-872. 被引量：1
-
6Gilani JA, Hameed K, Asghar AH, et al. Outcome of chemoradiation in treating carcinoma esophagus [ J ]. J Coil Physicians SurgPak, 2003, 13 (10) :562 -564.
-
7Cmsby TU, Brewster AE, Borley A, et al. Definitive chemoradi, ation in patients with inoperable oesophageal carcinoma [ J ]. Br JCaneer, 2004, 90 (1) :70 -75.
-
8全国肿瘤防治研究办公室 卫生部卫生统计信息中心.中国恶性肿瘤危险因素研究[M].北京:中国协和医科大学出版社,2003..
-
9王颖杰.时辰化疗在晚期食管癌治疗中的疗效观察[J].中华肿瘤防治杂志,2008,15(19):1500-1502. 被引量：4
-
10赵明宏,杨钧,周雪娥.氟尿嘧啶加顺铂静注治疗中、晚期食管癌20例[J].人民军医,2001,44(10):578-579. 被引量：2
-
1HOLOGIC 3D数字乳腺断层成像——刷新乳腺X射线检查新标准[J].中国医学装备,2017,14(7):158-158. 被引量：2
-
2吴丽芳,陈彩仁,蔡伟奕,王义来,孟庆勇.放射免疫诊断和治疗肺癌的研究进展[J].实用放射学杂志,2017,33(7):1132-1134. 被引量：6
-
3李玉成,程品晶,陈维军,许亚萍,李建龙,王振华,张强克.肺癌立体定向放射治疗中两种固定技术摆位误差的比较研究[J].中国肿瘤临床,2017,44(12):600-604. 被引量：26
